Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
New Jersey Hematology Oncology Associates
mi
from
Brick, NJ
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
New Jersey Hematology Oncology Associates
mi
from
Brick, NJ
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Montefiore Medical Center
mi
from
Bronx, NY
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
North Shore Hematology Oncology Associates
mi
from
East Setauket, NY
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
North Shore Hematology Oncology Associates
mi
from
East Setauket, NY
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Monter Cancer Center
mi
from
Lake Success, NY
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Monter Cancer Center
mi
from
Lake Success, NY
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Columbia University Medical Center
mi
from
New York, NY
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Gabrail Cancer Center Research LLC
mi
from
Canton, OH
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Carolina Blood and Cancer Care Associates PA
mi
from
Rock Hill, SC
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Carolina Blood and Cancer Care Associates PA
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Tennessee Oncology PLLC
mi
from
Chattanooga, TN
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Tennessee Oncology PLLC
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Tyler Hematology Oncology PA
mi
from
Tyler, TX
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Tyler Hematology Oncology PA
mi
from
Tyler, TX
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
University of Utah (Huntsman Cancer Hospital)
mi
from
Salt Lake City, UT
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
University of Utah (Huntsman Cancer Hospital)
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Utah Cancer Specialists
mi
from
Salt Lake City, UT
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Utah Cancer Specialists
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
University of Massachusetts Worcester
mi
from
Worcester, MA
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
University of Massachusetts Worcester
mi
from
Worcester, MA
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Oregon Health and Sciences University
mi
from
Portland, OR
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated:  3/1/2016
Royal Prince Alfred Hospital
mi
from
Camperdown,
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Enrolling
Updated: 3/1/2016
Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
The Robert H. Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
The Robert H. Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated:  3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial
Status: Enrolling
Updated: 3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Howard University Cancer Center
mi
from
Washington,
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Howard University Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County
mi
from
Mount Holly, NJ
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Hematology Oncology Associates of Central New York, PC - Northeast Center
mi
from
East Syracuse, NY
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Hematology Oncology Associates of Central New York, PC - Northeast Center
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
CCOP - Main Line Health
mi
from
Wynnewood, PA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
CCOP - Main Line Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Nashville General Hospital at Meharry
mi
from
Nashville, TN
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Nashville General Hospital at Meharry
mi
from
Nashville, TN
Click here to add this to my saved trials
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma
Status: Enrolling
Updated:  3/2/2016
H.Lee Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma
Status: Enrolling
Updated: 3/2/2016
H.Lee Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Status: Enrolling
Updated:  3/3/2016
University of Michigan,Department of Internal Med. Hematology- Oncology
mi
from
Ann Arbor, MI
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Status: Enrolling
Updated: 3/3/2016
University of Michigan,Department of Internal Med. Hematology- Oncology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status: Enrolling
Updated:  3/3/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status: Enrolling
Updated: 3/3/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status: Enrolling
Updated:  3/3/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status: Enrolling
Updated: 3/3/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status: Enrolling
Updated:  3/3/2016
Mt. Sinai Medical Center
mi
from
New York, NY
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status: Enrolling
Updated: 3/3/2016
Mt. Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status: Enrolling
Updated:  3/3/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy
Status: Enrolling
Updated: 3/3/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  3/3/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 3/3/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  3/3/2016
Mont Sinai Medical Center
mi
from
New York City, NY
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 3/3/2016
Mont Sinai Medical Center
mi
from
New York City, NY
Click here to add this to my saved trials